AVITA Medical Zukünftiges Wachstum
Future Kriterienprüfungen 5/6
AVITA Medical wird ein jährliches Gewinn- und Umsatzwachstum von 62.9% bzw. 17.9% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 50.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 1066.5% betragen.
Wichtige Informationen
62.9%
Wachstumsrate der Gewinne
50.70%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 25.2% |
| Wachstumsrate der Einnahmen | 17.9% |
| Zukünftige Eigenkapitalrendite | 1,066.50% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 27 May 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Narrativ-Update • Jun 14
RCEL: Execution And Cash Strength Are Expected To Drive Future Upside
Narrative update The analyst price target for AVITA Medical has risen by $2.50 to $6.00, with analysts highlighting the recent stock pullback, the latest Q1 revenue level, and expectations for execution and cash position as key supports for this revision. Analyst Commentary Bullish analysts are pointing to the recent price target reset and rating change as a sign of renewed confidence in AVITA Medical after the latest quarterly update.Narrativ-Update • May 31
RCEL: Market Recovery And Cash Progress Are Expected To Drive Upside
Analysts have slightly adjusted the AVITA Medical price target to reflect updated assumptions for growth, margins and future P/E. They continue to reference Street research that highlights improving execution, Lake Street’s higher $6 target, and Northland's $10 target supported by expectations for revenue recovery, cash progress and a large addressable market.
Narrativ-Update • May 10
RCEL: Low Market Penetration And FY27 Cash Breakeven Will Drive Repricing
Analysts have trimmed their price target for AVITA Medical to $5.49 from $5.52, reflecting updated assumptions on discount rate, revenue growth, profit margin, and future P/E after recent research highlighted low current market penetration, a roughly $1.3b total addressable market, reimbursement stabilization, and an outlook for potential cash breakeven during FY27. Analyst Commentary Recent research points to a mixed backdrop for AVITA Medical, with analysts updating their models around a roughly $1.3b total addressable market, low current market penetration of about 5%, and expectations tied to reimbursement trends and the path toward a potential cash breakeven during FY27.Narrativ-Update • Apr 25
RCEL: Market Penetration And Burn Preparedness Agreement Will Support Constructive Upside
Narrative Update on AVITA Medical The Analyst Price Target for AVITA Medical has been adjusted from $10.02 to about $10.16. Analysts point to updated views on revenue growth and profit margins, as well as recent Northland research highlighting market penetration, product differentiation, reimbursement trends and the path toward cash breakeven as key supports for this change.Narrativ-Update • Apr 11
RCEL: Reimbursement Stability And FY27 Cash Breakeven Frame Balanced Risk Reward Outlook
The analyst price target for AVITA Medical has been revised slightly higher to reflect an updated fair value of about $5.52, up from roughly $5.33. Analysts point to expectations for revenue growth, stable profit margins, and recent research citing product differentiation, reimbursement stabilization, and progress toward cash breakeven as key drivers of their refreshed view.Narrativ-Update • Mar 28
RCEL: Reimbursement Stability And FY27 Cash Breakeven Drive Bullish Rerating Potential
Analysts have trimmed their blended valuation for AVITA Medical, with the updated fair value estimate easing from about $5.44 to $5.33 per share. This reflects revised assumptions on revenue growth, profit margins, and a lower future P/E multiple informed by recent research that highlights both the pullback in the stock and expectations for double digit top line expansion over time.Narrativ-Update • Mar 13
RCEL: Reimbursement Stability And Cash Breakeven Path Will Underpin Renewed Market Confidence
Analysts have lifted their AVITA Medical price target to $10, supported by expectations for renewed double digit revenue growth from a roughly $1.3b addressable market, reimbursement stabilization, and a path to potential cash breakeven around FY27. Analyst Commentary Recent coverage has highlighted a mixed but generally constructive view on AVITA Medical, with the latest initiation pointing to a $10 price target.Narrativ-Update • Feb 27
RCEL: Refined Earnings Assumptions And Burn Data Will Support Constructive Upside
Analysts have nudged their average price target on AVITA Medical up by $0.50 per share, citing updated assumptions around revenue growth, profit margins and P/E multiples that modestly refine their valuation models. Analyst Commentary Recent bullish analysts have framed the $0.50 uplift in the average price target as a refinement rather than a wholesale reset.Narrativ-Update • Feb 13
RCEL: Ongoing Burn And Wound Data Will Support Constructive Long-Term Upside
Analysts have adjusted their price target on AVITA Medical to $10.07 from $14.10, reflecting updated views on fair value, discount rate, revenue growth and profit margin assumptions that are broadly consistent with recent Street research, including the modest target raise cited by Lake Street. Analyst Commentary Recent price target work on AVITA Medical points to a more constructive tone among bullish analysts, even if some models still embed conservative assumptions on execution and profitability.Narrativ-Update • Jan 30
RCEL: Elevated Expectations For 2026 Guidance Will Expose Fragile Market Confidence
Narrative Update: AVITA Medical Analysts have raised their price target on AVITA Medical to about US$3.61 from roughly US$3.00, citing updated assumptions for fair value, discount rate, revenue growth, profit margins, and future P/E as key factors behind the revised assessment. Analyst Commentary Even with a higher price target around US$3.61, bearish analysts remain cautious and describe the move as a fine tuning of assumptions rather than a strong endorsement of upside potential.Analyseartikel • Jan 24
There's No Escaping AVITA Medical, Inc.'s (NASDAQ:RCEL) Muted Revenues Despite A 26% Share Price Rise
AVITA Medical, Inc. ( NASDAQ:RCEL ) shareholders would be excited to see that the share price has had a great month...
Narrativ-Update • Jan 16
RCEL: Two Year Revenue Guidance Reset Will Support Bullish Repricing
Analysts have adjusted their price target for AVITA Medical, reflecting a lower implied fair value of $6.98, down from $7.32. They cite updated assumptions around revenue growth, profit margins, and a reduced future P/E multiple.Analyseartikel • Nov 09
AVITA Medical, Inc. (NASDAQ:RCEL) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
AVITA Medical, Inc. ( NASDAQ:RCEL ) missed earnings with its latest quarterly results, disappointing overly-optimistic...Narrativ-Update • Nov 08
RCEL: Leadership Transition And Guidance Reset Will Drive Second Half Recovery
Analysts have lowered their price target for AVITA Medical from $8.00 to $4.00. They cite weaker-than-expected Q3 revenue, leadership changes, and the need to amend debt agreements as key factors in their revised outlook.Analyseartikel • Oct 03
AVITA Medical, Inc. (NASDAQ:RCEL) Surges 28% Yet Its Low P/S Is No Reason For Excitement
AVITA Medical, Inc. ( NASDAQ:RCEL ) shareholders would be excited to see that the share price has had a great month...Narrativ-Update • Sep 17
Medicare Resolution And Trauma Expansion Will Shape Future Wound Care
Analysts have markedly reduced AVITA Medical’s price target from $9.60 to $8.26 amid lowered guidance, recurring earnings misses, and ongoing reimbursement headwinds that are pressuring demand and raising solvency concerns despite management’s optimism for a second-half recovery. Analyst Commentary Materially lowered guidance has prompted a significant reset of expectations, but management maintains confidence in a second half recovery.Narrativ-Update • Aug 15
Medicare Resolution And Trauma Expansion Will Shape Future Wound Care
AVITA Medical’s consensus price target remains unchanged as analysts respond to materially reduced guidance and persistent reimbursement issues—with bulls viewing the lowered expectations as prudent and bears citing execution risks and near-term revenue headwinds—leaving the fair value steady at $9.60. Analyst Commentary Materially reduced guidance led to significant downward revisions in price targets.Analyseartikel • Aug 10
AVITA Medical, Inc. (NASDAQ:RCEL) Not Doing Enough For Some Investors As Its Shares Slump 25%
Unfortunately for some shareholders, the AVITA Medical, Inc. ( NASDAQ:RCEL ) share price has dived 25% in the last...Analyseartikel • May 29
Shareholders Will Probably Not Have Any Issues With AVITA Medical, Inc.'s (NASDAQ:RCEL) CEO Compensation
Key Insights AVITA Medical will host its Annual General Meeting on 4th of June CEO Jim Corbett's total compensation...
Neues Narrativ • Apr 24
PermeaDerm And Cohealyx Will Open International Markets
Launching new products and expanding internationally are expected to drive significant revenue growth and market penetration.Analyseartikel • Mar 06
Investors Don't See Light At End Of AVITA Medical, Inc.'s (NASDAQ:RCEL) Tunnel
AVITA Medical, Inc.'s ( NASDAQ:RCEL ) price-to-sales (or "P/S") ratio of 3.5x might make it look like a strong buy...Analyseartikel • Dec 30
Is AVITA Medical (NASDAQ:RCEL) Using Debt Sensibly?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyseartikel • Dec 03
AVITA Medical, Inc.'s (NASDAQ:RCEL) Shares Bounce 26% But Its Business Still Trails The Industry
AVITA Medical, Inc. ( NASDAQ:RCEL ) shares have continued their recent momentum with a 26% gain in the last month...Analyseartikel • Oct 04
AVITA Medical, Inc.'s (NASDAQ:RCEL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
AVITA Medical, Inc. ( NASDAQ:RCEL ) shares have continued their recent momentum with a 26% gain in the last month...Analyseartikel • Aug 11
AVITA Medical, Inc. (NASDAQ:RCEL) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Shareholders of AVITA Medical, Inc. ( NASDAQ:RCEL ) will be pleased this week, given that the stock price is up 16% to...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 129 | 4 | 4 | 12 | 6 |
| 12/31/2027 | 106 | -18 | -9 | -1 | 9 |
| 12/31/2026 | 83 | -35 | -30 | -28 | 9 |
| 3/31/2026 | 72 | -45 | -32 | -31 | N/A |
| 12/31/2025 | 72 | -49 | -33 | -31 | N/A |
| 9/30/2025 | 72 | -49 | -37 | -34 | N/A |
| 6/30/2025 | 75 | -52 | -42 | -36 | N/A |
| 3/31/2025 | 72 | -57 | -47 | -38 | N/A |
| 12/31/2024 | 64 | -62 | -58 | -49 | N/A |
| 9/30/2024 | 60 | -57 | -60 | -52 | N/A |
| 6/30/2024 | 54 | -50 | -58 | -53 | N/A |
| 3/31/2024 | 51 | -45 | -52 | -50 | N/A |
| 12/31/2023 | 50 | -35 | -39 | -38 | N/A |
| 9/30/2023 | 45 | -34 | -32 | -31 | N/A |
| 6/30/2023 | 41 | -31 | -25 | -24 | N/A |
| 3/31/2023 | 37 | -26 | -20 | -19 | N/A |
| 12/31/2022 | 34 | -27 | -20 | -19 | N/A |
| 9/30/2022 | 32 | -30 | -21 | -21 | N/A |
| 6/30/2022 | 30 | -30 | -19 | -18 | N/A |
| 3/31/2022 | 32 | -29 | -19 | -19 | N/A |
| 12/31/2021 | 33 | -25 | -19 | -18 | N/A |
| 9/30/2021 | 31 | -22 | -20 | -19 | N/A |
| 6/30/2021 | 29 | -27 | -27 | -26 | N/A |
| 3/31/2021 | 23 | -35 | -29 | -28 | N/A |
| 12/31/2020 | 18 | -44 | -28 | -27 | N/A |
| 9/30/2020 | 16 | -49 | -27 | -26 | N/A |
| 6/30/2020 | 14 | -42 | -24 | -23 | N/A |
| 3/31/2020 | 12 | -36 | -24 | -23 | N/A |
| 12/31/2019 | 11 | -28 | N/A | -21 | N/A |
| 9/30/2019 | 8 | -23 | N/A | -21 | N/A |
| 6/30/2019 | 5 | -25 | N/A | -19 | N/A |
| 3/31/2019 | 4 | -22 | N/A | -18 | N/A |
| 12/31/2018 | 2 | -18 | N/A | -13 | N/A |
| 9/30/2018 | 1 | -15 | N/A | -13 | N/A |
| 6/30/2018 | 1 | -13 | N/A | -13 | N/A |
| 3/31/2018 | 1 | -12 | N/A | -11 | N/A |
| 12/31/2017 | 1 | -11 | N/A | -9 | N/A |
| 9/30/2017 | 1 | -10 | N/A | -8 | N/A |
| 6/30/2017 | 1 | -9 | N/A | -7 | N/A |
| 3/31/2017 | 1 | -8 | N/A | -6 | N/A |
| 12/31/2016 | 1 | -7 | N/A | -6 | N/A |
| 9/30/2016 | 1 | -8 | N/A | -6 | N/A |
| 6/30/2016 | 1 | -8 | N/A | -6 | N/A |
| 3/31/2016 | 1 | -8 | N/A | -7 | N/A |
| 12/31/2015 | 1 | -7 | N/A | -7 | N/A |
| 9/30/2015 | 1 | -6 | N/A | -5 | N/A |
| 6/30/2015 | 1 | -6 | N/A | -5 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: RCEL wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (3.5%).
Ertrag vs. Markt: RCEL wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.
Hohe Wachstumserträge: RCEL wird voraussichtlich in den nächsten 3 Jahren rentabel werden.
Einnahmen vs. Markt: RCELDie Einnahmen des Unternehmens (17.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (12.8% pro Jahr).
Hohe Wachstumseinnahmen: RCELDie Einnahmen des Unternehmens (17.9% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: RCELDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich sehr hoch sein (1066.5%).
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/06/23 19:42 |
| Aktienkurs zum Tagesende | 2026/06/23 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
AVITA Medical, Inc. wird von 14 Analysten beobachtet. 9 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| John Hester | Bell Potter |
| Lyanne Harrison | BofA Global Research |
| Laura McGuigan | B. Riley Securities, Inc. |